MannKind Corp (MNKD) reports a 37% revenue increase, driven by Tyvaso DPI and Afrezza, while navigating market challenges and ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue ...

Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...

As of the latest trading close, MNKD, a Healthcare sector stock, is trading 1.57% below its 52-week high but remains 134.70% above its 52-week low. The Average True Range (ATR) (14 days) of 0.25 ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...

Leerink Partners has recently resumed MannKind Corp (MNKD) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on June 13, 2024, Rodman & Renshaw had initiated ...

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

In a report released on November 7, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind (MNKD – Research Report), ...

In a report released today, Gregory Renza from RBC Capital maintained a Hold rating on MannKind (MNKD – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $7.39.

International Assets Investment Management LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 511 ...